Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
Angotzi F, Petrella M, Berno T, Binotto G, Bonetto G, Branca A, Carraro M, Cavaretta CA, Cellini A, D'Amore F, Forlani L, Gianesello I, Gurrieri C, Imbergamo S, Lessi F, Maroccia A, Mazzetto F, Pavan L, Pezone S, Piazza F, Pravato S, Ruocco V, Scapinello G, Vianello F, Zambello R, Zatta I, Zoletto S, Padoan A, Trentin L, Visentin A. Angotzi F, et al. Among authors: pravato s. Front Oncol. 2023 Jun 22;13:1212752. doi: 10.3389/fonc.2023.1212752. eCollection 2023. Front Oncol. 2023. PMID: 37427126 Free PMC article.
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study.
Visentin A, Mauro FR, Catania G, Fresa A, Vitale C, Sanna A, Mattiello V, Cibien F, Sportoletti P, Gentile M, Rigolin GM, Quaglia FM, Murru R, Gozzetti A, Molica S, Marchetti M, Pravato S, Angotzi F, Cellini A, Scarfò L, Reda G, Coscia M, Laurenti L, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: pravato s. Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022. Front Oncol. 2022. PMID: 36479077 Free PMC article.
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A, Molinari MC, Pravato S, Cellini A, Angotzi F, Cavaretta CA, Ruocco V, Imbergamo S, Piazza F, Proietti G, Mauro FR, Trentin L. Visentin A, et al. Among authors: pravato s. Curr Oncol. 2022 Dec 25;30(1):274-283. doi: 10.3390/curroncol30010022. Curr Oncol. 2022. PMID: 36661671 Free PMC article.
From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.
Visentin A, Pravato S, Castellani F, Campagnolo M, Angotzi F, Cavarretta CA, Cellini A, Ruocco V, Salvalaggio A, Tedeschi A, Trentin L, Briani C. Visentin A, et al. Among authors: pravato s. Cancers (Basel). 2022 Mar 18;14(6):1562. doi: 10.3390/cancers14061562. Cancers (Basel). 2022. PMID: 35326711 Free PMC article. Review.
Anaemia during venetoclax ramp-up phase: Do not forget unusual causes.
Cavarretta CA, Visentin A, Pravato S, Piva E, Piazza F, Basso D, Trentin L. Cavarretta CA, et al. Among authors: pravato s. Int J Lab Hematol. 2022 Oct;44(5):e211-e214. doi: 10.1111/ijlh.13875. Epub 2022 May 11. Int J Lab Hematol. 2022. PMID: 35538897 No abstract available.
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A, Facco M, Gurrieri C, Pagnin E, Martini V, Imbergamo S, Frezzato F, Trimarco V, Severin F, Raggi F, Scomazzon E, Pravato S, Piazza F, Semenzato G, Trentin L. Visentin A, et al. Among authors: pravato s. Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):678-685.e4. doi: 10.1016/j.clml.2019.03.002. Epub 2019 Mar 11. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31371221
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.
Visentin A, Frezzato F, Severin F, Imbergamo S, Pravato S, Romano Gargarella L, Manni S, Pizzo S, Ruggieri E, Facco M, Brunati AM, Semenzato G, Piazza F, Trentin L. Visentin A, et al. Among authors: pravato s. Onco Targets Ther. 2020 Sep 29;13:9679-9688. doi: 10.2147/OTT.S268899. eCollection 2020. Onco Targets Ther. 2020. PMID: 33061448 Free PMC article. Review.
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Visentin A, Imbergamo S, Scomazzon E, Pravato S, Frezzato F, Bonaldi L, Pizzi M, Vio S, Gregianin M, Burei M, Facco M, Semenzato G, Piazza F, Trentin L. Visentin A, et al. Among authors: pravato s. Br J Haematol. 2019 Apr;185(1):193-197. doi: 10.1111/bjh.15440. Epub 2018 Jul 5. Br J Haematol. 2019. PMID: 29974955 Free article. No abstract available.
27 results